PharmaLogic announced the opening of its new PET radiopharmaceutical manufacturing facility in Atlanta, Georgia. The facility represents a significant milestone in PharmaLogic's commitment to expanding domestic radiopharmaceutical manufacturing infrastructure, advancing patient access to novel diagnostic and therapeutic radiopharmaceuticals across the Southeast and beyond.
Etienne Montagut, President & CEO of PharmaLogic, said: "The opening of our Atlanta facility marks another critical step in our $250 million investment to address the deficit of radiopharmaceutical infrastructure in the U.S. This state-of-the-art PET manufacturing facility will bring advanced radiopharmaceuticals to patients in the Southeast and surrounding areas, and will serve as a hub for supporting the development of next-generation radiopharmaceuticals."
The Atlanta facility strengthens PharmaLogic's expanding platform of radiopharmaceutical production and research facilities. Equipped with cutting-edge PET manufacturing technology, the facility is designed to expand current production capacity while providing dedicated resources for the research and development of novel radiopharmaceuticals. Its strategic location in Atlanta will enable faster, more reliable distribution of time-sensitive radiopharmaceuticals to hospitals and imaging centers across the region.
The opening continues PharmaLogic's national expansion, following the recent openings of new facilities in Cincinnati, Ohio; the Bronx, New York; Salt Lake City, Utah; and Los Angeles, California.